Document is current

Article History

Accepted: 17 December 2024

First Online: 17 January 2025

Declarations

:

: Open access funding provided by Medical University of Vienna.

: E.V. Klocker has received personal fees /travel support from AstraZeneca, DaiichiSankyo, EliLilly, Gilead, Novartis, Roche, Stemline, and PierreFabre. D. Egle reports personal fees/travel support from Amgen, AstraZeneca, Daiichi-Sankyo, Gilead, Lilly, Mennarini, MSD, Novartis, Pfizer, Roche, Sandoz, Seagen, and Sirius Medical. R. Bartsch reports an advisory role with Astra-Zeneca, Daiichi, Eisai, Eli-Lilly, Gilead, Gruenenthal, MSD, Novartis, Pfizer, Pierre-Fabre, Puma, Roche, Seagen, and Stemline. Lecture Honoraria from Astra-Zeneca, BMS, Daichi, Eisai, Eli-Lilly, Gilead, Gruenenthal, MSD, Novartis, Pfizer, Pierre-Fabre, Roche, and Seagen. Research Support from Daiichi, MSD, Novartis, and Roche. G. Rinnerthaler reports Honoraria from Amgen, AstraZeneca, Daiichi Sankyo, Eli Lilly, Gilead, MSD, Novartis, Pfizer, Roche, Seagen, Stemline, and BMS. Consulting or Advisory Role with Amgen, AstraZeneca, Daiichi Sankyo, Eli Lilly, Gilead, MSD, Novartis, Pfizer, Pierre Fabre, Roche, and Stemline. Travel, accommodation, expenses from Amgen, Daiichi Sankyo, Eli Lilly, Gilead, Merck, Pfizer, and Roche. M. Gnant reports personal fees/travel support from Amgen, AstraZeneca, Bayer, DaiichiSankyo, EliLilly, EPG Health (IQVIA), Menarini-Stemline, MSD, Novartis, PierreFabre, and Veracyte; an immediate family member is employed by Sandoz.

: Not applicable; no ethics approval was necessary for this review.

: Not applicable.

: Not applicable.

: Not applicable.

: No datasets were generated or analyzed during the current study.

: All authors contributed to the conception and design. The first manuscript outline was developed by MG, the first draft of the full manuscript was written by EVK and GR, and further developed by all authors. All authors read and approved the final manuscript.